All In Biotech

Free tool

FAERS Monitor: Palynziq

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761079 or its brand name (Palynziq, Pegvaliase-Pqpz). Reports on generic versions are filed under their own applications.

Reports

8,518

Serious

1,340

16% of reports

Hospitalization

314

Death reported

12

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • arthralgia1,463
  • injection site reaction957
  • injection site erythema794
  • injection site swelling584
  • rash533
  • urticaria523
  • headache461
  • injection site pain448
  • injection site pruritus389
  • fatigue386
  • pruritus359
  • hypersensitivity357
  • dizziness347
  • nausea342
  • anaphylactic reaction337

Reports by year received

View as table
YearReports
2018156
20191,038
20201,207
20211,114
2022860
20231,027
20241,148
20251,082
2026886

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,641 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
injection site reactionSignal95734.832.831,059
injection site swellingSignal58419.017.59,876
injection site erythemaSignal79415.914.911,066
anaphylactic reactionSignal33715.113.64,423
injection site pruritusSignal38914.413.14,831
arthralgiaSignal1,4638.78.310,150
urticariaSignal5237.77.13,072
hypersensitivitySignal3574.84.31,063
injection site painSignal4483.63.3854
rashSignal5333.02.8733
pruritusSignal3592.32.1269
headache4611.81.7173
dizziness3471.71.6106
fatigue3861.21.116
nausea3421.11.01

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.